Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ana Vivancos

Showing results (61-70 of 103) with videos related to

Pageof 11
Sort By:
Nature Communications|November 4, 2025
HER2DX in older patients with HER2-positive early breast cancer: extended follow-up from the RESPECT trial of trastuzumab ± chemotherapyKazuki Nozawa, Masataka Sawaki, Yukari Uemura, et al.
Cancers|July 29, 2023
Expression of TILs and Patterns of Gene Expression from Paired Samples of Malignant Pleural Mesothelioma (MPM) PatientsSusana Cedres, Garazi Serna, Alberto Gonzalez-Medina, et al.
BMC Cancer|February 7, 2020
Clinical value of next generation sequencing of plasma cell-free DNA in gastrointestinal stromal tumorsCésar Serrano, Ana Vivancos, Antonio López-Pousa, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 12, 2021
Biomarker Analysis of the Phase III NALA Study of Neratinib + Capecitabine versus Lapatinib + Capecitabine in Patients with Previously Treated Metastatic Breast CancerCristina Saura, Judit Matito, Mafalda Oliveira, et al.
Molecular Oncology|April 25, 2023
Genomically matched therapy in refractory colorectal cancer according to ESMO Scale for Clinical Actionability of Molecular Targets: experience of a comprehensive cancer centre networkNúria Mulet Margalef, Carmen Castillo, Miguel Mosteiro, et al.
Molecular Oncology|July 20, 2019
Impact of circulating tumor DNA mutant allele fraction on prognosis in RAS-mutant metastatic colorectal cancerElena Elez, Chiara Chianese, Enrique Sanz-García, et al.
The Oncologist|August 22, 2018
Clinicopathological and Molecular Characterization of Metastatic Gastrointestinal Stromal Tumors with Prolonged Benefit to Frontline ImatinibCésar Serrano, Xavier García-Del-Muro, Claudia Valverde, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 15, 2015
MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal CancerCelina García-García, Martín A Rivas, Yasir H Ibrahim, et al.
Nature Communications|November 12, 2022
pTINCR microprotein promotes epithelial differentiation and suppresses tumor growth through CDC42 SUMOylation and activationOlga Boix, Marion Martinez, Santiago Vidal, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 1, 2021
High <i>FGFR1-4</i> mRNA Expression Levels Correlate with Response to Selective FGFR Inhibitors in Breast CancerMònica Sánchez-Guixé, Cinta Hierro, José Jiménez, et al.
Pageof 11

Showing results (61-70 of 103) with videos related to

Sort By:
Pageof 11
Nature Communications|November 4, 2025
HER2DX in older patients with HER2-positive early breast cancer: extended follow-up from the RESPECT trial of trastuzumab ± chemotherapyKazuki Nozawa, Masataka Sawaki, Yukari Uemura, et al.
Cancers|July 29, 2023
Expression of TILs and Patterns of Gene Expression from Paired Samples of Malignant Pleural Mesothelioma (MPM) PatientsSusana Cedres, Garazi Serna, Alberto Gonzalez-Medina, et al.
BMC Cancer|February 7, 2020
Clinical value of next generation sequencing of plasma cell-free DNA in gastrointestinal stromal tumorsCésar Serrano, Ana Vivancos, Antonio López-Pousa, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 12, 2021
Biomarker Analysis of the Phase III NALA Study of Neratinib + Capecitabine versus Lapatinib + Capecitabine in Patients with Previously Treated Metastatic Breast CancerCristina Saura, Judit Matito, Mafalda Oliveira, et al.
Molecular Oncology|April 25, 2023
Genomically matched therapy in refractory colorectal cancer according to ESMO Scale for Clinical Actionability of Molecular Targets: experience of a comprehensive cancer centre networkNúria Mulet Margalef, Carmen Castillo, Miguel Mosteiro, et al.
Molecular Oncology|July 20, 2019
Impact of circulating tumor DNA mutant allele fraction on prognosis in RAS-mutant metastatic colorectal cancerElena Elez, Chiara Chianese, Enrique Sanz-García, et al.
The Oncologist|August 22, 2018
Clinicopathological and Molecular Characterization of Metastatic Gastrointestinal Stromal Tumors with Prolonged Benefit to Frontline ImatinibCésar Serrano, Xavier García-Del-Muro, Claudia Valverde, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 15, 2015
MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal CancerCelina García-García, Martín A Rivas, Yasir H Ibrahim, et al.
Nature Communications|November 12, 2022
pTINCR microprotein promotes epithelial differentiation and suppresses tumor growth through CDC42 SUMOylation and activationOlga Boix, Marion Martinez, Santiago Vidal, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 1, 2021
High <i>FGFR1-4</i> mRNA Expression Levels Correlate with Response to Selective FGFR Inhibitors in Breast CancerMònica Sánchez-Guixé, Cinta Hierro, José Jiménez, et al.
Pageof 11